Editor’s Choice for May 2018
21 May 2018
Editor’s Choice for May 2018
Editor's Choice for April 2018
Phase I taselisib results and a cell-free DNA assay
One off PSA prostate screening for men does not save lives
The Integrative Cancer Epidemiology Programme
Editor’s Choice for March 2018
Management of marker negative stage II testicular cancer
Editor's Choice for February 2018
Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma
Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma
Genetic mutations: New therapeutic avenues in metastatic prostate cancer
6-factor prognostic model for patients with advanced urothelial carcinoma